BioSpace News Archive

Safe and Wenzel Spine, having recently signed two business agreements, are joining forces during the North American Spine Society meeting in Chicago between the October 11 and 14th, 2022.

Abivax SA announces that the first patient has been enrolled in the US into its global phase 3 clinical program with product candidate obefazimod for the treatment of moderate to severe ulcerative colitis.

Fresenius Kabi announced the successful smart pump interoperability of its Ivenix Infusion System at Fort HealthCare, a regional health care provider in Wisconsin.

Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of central nervous system diseases, today announced the closing of its previously announced underwritten public offering of 3,636,365 common and pre-funded units.

PDS Biotechnology Corporation today announced expanded interim data in the Phase 2 clinical trial investigating the PDS0101-based triple combination therapy in advanced human papillomavirus (HPV)-positive cancers.

BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it will be collaborating with NOCD, an organization that facilitates access to online therapy for people with obsessive-compulsive disorder (OCD) through its innovative telehealth platform.

Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to the development of gut-targeted, small molecule therapeutics for neurological conditions and oncology, today announced that it is building on its clinical development science and operations capabilities through recent key appointments.

The Board of Directors has decided that the General Meeting is to be held only through postal voting in accordance with temporary legislation applicable since March 1, 2022.

Nexus Spine, a developer of biomechanically-advanced solutions for spinal pathologies, today announced that its Tranquil ™ interbody fusion technology has reached 5,000 implantations.

Graphite Bio Announces Participation in 50th Annual Sickle Cell Disease Association of America National Convention.